{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"contributor": "", "original": "By ERIC LIPTON and RACHEL ABRAMS", "person": [{"firstname": "Eric", "rank": 1, "lastname": "LIPTON", "organization": "", "role": "reported"}, {"firstname": "Rachel", "rank": 2, "lastname": "ABRAMS", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "2082", "keywords": [{"rank": "1", "value": "Mylan Inc", "is_major": "Y", "name": "organizations"}, {"rank": "2", "value": "Epinephrine (Drug)", "is_major": "Y", "name": "subject"}, {"rank": "3", "value": "Lobbying and Lobbyists", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "Law and Legislation", "is_major": "N", "name": "subject"}, {"rank": "6", "value": "Health Insurance and Managed Care", "is_major": "Y", "name": "subject"}, {"rank": "7", "value": "United States Preventive Services Task Force", "is_major": "N", "name": "organizations"}], "lead_paragraph": "Inclusion on a federal list would mean Mylan could keep its list price high \u2014 or even raise it \u2014 without patients\u2019 complaining. But consumers would feel it indirectly.", "pub_date": "2016-09-16T07:30:34+0000", "document_type": "article", "source": "The New York Times", "snippet": "Inclusion on a federal list would mean Mylan could keep its list price high \u2014 or even raise it \u2014 without patients\u2019 complaining. But consumers would feel it indirectly....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbWide.jpg"}, {"height": 391, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "391", "xlarge": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/09/16/business/epipen-maker-mylan-preventative-drug-campaign.html", "slideshow_credits": null, "blog": [], "_id": "57db9f9f95d0e021d7986943", "headline": {"main": "EpiPen Maker Lobbies to Shift High Costs to Others", "print_headline": "Tactic by Maker of EpiPen Could Quell Protests"}}